ストックスクリーナーアプリを入手
0.3975
7.37%
0.0273
アフターアワーズ：
.40
0.0025
+0.63%
前日終値:
$0.3702
開ける：
$0.37
24時間の取引高:
732.02K
Relative Volume:
1.45
時価総額：
$26.64M
収益：
-
当期純損益:
$-126.61M
株価収益率:
-0.2028
EPS:
-1.96
ネットキャッシュフロー:
$-60.14M
1週間 パフォーマンス:
-13.00%
1か月 パフォーマンス:
-25.99%
6か月 パフォーマンス:
-83.30%
1年 パフォーマンス:
-90.35%
1日の値動き範囲:
$0.36
$0.4141
1週間の範囲:
$0.356
$0.4626
52週間の値動き範囲:
$0.356
$4.52
Generation Bio Co Stock (GBIO) Company Profile
GBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GBIO
Generation Bio Co
|
0.3975 | 26.64M | 0 | -126.61M | -60.14M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Generation Bio Co Stock (GBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-10-19 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2022-11-08 | 開始されました | Canaccord Genuity | Buy |
| 2021-12-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-06-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-02-24 | 開始されました | William Blair | Outperform |
| 2021-02-18 | 開始されました | Needham | Buy |
| 2020-07-07 | 開始されました | Cowen | Outperform |
| 2020-07-07 | 開始されました | JP Morgan | Overweight |
| 2020-07-07 | 開始されました | Jefferies | Buy |
| 2020-07-07 | 開始されました | Wedbush | Outperform |
すべてを表示
Generation Bio Co (GBIO) 最新ニュース
Generation Bio stock hits 52-week low at $0.4 amid steep decline - Investing.com Australia
Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference - The Manila Times
Generation Bio Takes Center Stage: CEO Fireside Chat at Major Healthcare Conference - Stock Titan
Charles Schwab Investment Management Inc. Cuts Stake in Generation Bio Co. (NASDAQ:GBIO) - Defense World
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Generation Bio Co. (GBIO) Reports Q4 Loss, Tops Revenue Estimates - MSN
Generation Bio stock hits 52-week low at $0.47 By Investing.com - Investing.com South Africa
Generation Bio stock hits 52-week low at $0.47 - Investing.com
Generation Bio’s (GBIO) Buy Rating Reaffirmed at Canaccord Genuity Group - Defense World
Generation Bio’s SWOT analysis: stock pivots to T-cell focus amid market caution By Investing.com - Investing.com South Africa
Generation Bio’s SWOT analysis: stock pivots to T-cell focus amid market caution - Investing.com Australia
Generation Bio’s (GBIO) Outperform Rating Reiterated at Wedbush - Defense World
Generation Bio Co. (NASDAQ:GBIO) Not Doing Enough For Some Investors As Its Shares Slump 29% - Simply Wall St
Generation Bio Co. Advances in Autoimmune Therapeutics - TipRanks
Generation Bio Co reports results for the quarter ended December 31Earnings Summary - TradingView
Generation Bio stock holds Market Perform rating at JMP - Investing.com India
Generation Bio stock holds Market Perform rating at JMP By Investing.com - Investing.com UK
Generation Bio earnings missed by $0.02, revenue topped estimates - Investing.com South Africa
Generation Bio Co (GBIO) Q4 2024 Earnings: EPS Misses Estimate o - GuruFocus.com
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Generation Bio Co. Advances T Cell-Selective siRNA Therapeutics for Autoimmune Diseases, Announces Robust Financial Position - Nasdaq
Generation Bio's Breakthrough: 98% T Cell Success Powers $185M Cash Runway Through 2027 - StockTitan
Generation Bio Co (GBIO)’s stock rises to 0.52 per share - US Post News
Generation Bio stock hits 52-week low at $0.52 By Investing.com - Investing.com Australia
A Guide To The Risks Of Investing In Generation Bio Co (GBIO) - Knox Daily
Generation Bio stock hits 52-week low at $0.52 - Investing.com
Generation Bio (GBIO) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Contrasting Generation Bio (NASDAQ:GBIO) & Anthera Pharmaceuticals (OTCMKTS:ANTH) - Defense World
Generation Bio faces Nasdaq delisting over share price By Investing.com - Investing.com Canada
Generation Bio faces Nasdaq delisting over share price - Investing.com India
Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Generation Bio's Autoimmune Disease Strategy Transform T Cell Treatment? CEO Reveals Plans - StockTitan
Kineticos Launches Kinvard Bio to Advance Next-Generation Antibiotics in the Fight Against Antimicrobial Resistance - PR Newswire
Generation Bio stock hits 52-week low at $0.6 amid sharp decline - Investing.com Nigeria
Generation Bio stock hits 52-week low at $0.6 amid sharp decline By Investing.com - Investing.com South Africa
Spore.Bio raises €22 million to deploy a new generation of AI-based microbiology testing - EU-Startups
Generation Bio Co (GBIO) 財務データ
収益
当期純利益
現金流量
EPS
1.23%
1.63%
大文字化:
|
ボリューム (24 時間):